Common Contracts
313 similar Underwriting Agreement contracts by Amylyx Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc., Atlas Energy Solutions Inc., others
Class A Common Stock Underwriting AgreementUnderwriting Agreement • April 16th, 2024 • Rubrik, Inc. • Services-prepackaged software
Rubrik, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ • ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ • ] additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.000025 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Contineum Therapeutics, Inc. (a Delaware corporation) [•] Shares of Class A Common Stock Underwriting AgreementUnderwriting Agreement • April 1st, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Boundless Bio, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 21st, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations
Boundless Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”
Arcutis Biotherapeutics, Inc. Common Stock, Par Value $0.0001 per Share Underwriting AgreementUnderwriting Agreement • March 4th, 2024 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations
ArriVent BioPharma, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 22nd, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
Goldman Sachs & Co. LLC Jefferies LLC Citigroup Global Markets Inc. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto,
Underwriting AgreementUnderwriting Agreement • August 14th, 2023 • Innoviz Technologies Ltd. • Motor vehicle parts & accessories
Innoviz Technologies Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 26,000,000 ordinary shares, no par value per share, of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to 3,900,000 additional ordinary shares, no par value per share, of the Company (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
Flywire Corporation Common Stock Underwriting AgreementUnderwriting Agreement • August 11th, 2023 • Flywire Corp • Services-business services, nec
Flywire Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 8,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,200,000 additional shares (the “Optional Shares”) of voting common stock, $0.0001 par value per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Aurora Innovation, Inc. Class A Common Stock, par value $0.00001 Underwriting AgreementUnderwriting Agreement • July 19th, 2023 • Aurora Innovation, Inc. • Services-computer integrated systems design
Aurora Innovation, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 73,333,333 shares the “Firm Shares”) and, at the election of the Underwriters, up to 10,999,999 additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.00001 (“Class A Common Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Kodiak Gas Services, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • July 5th, 2023 • Kodiak Gas Services, Inc. • Natural gas transmission
Kodiak Gas Services Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 16,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,400,000 additional shares (the “Optional Shares”) of common stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Sagimet Biosciences Inc. Series A Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • July 3rd, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations
Sagimet Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”) and in the manner contemplated by this Agreement, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Series A common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • May 24th, 2023 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations
Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 11,125,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,668,750 additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • May 9th, 2023 • 4D Molecular Therapeutics, Inc. • Biological products, (no disgnostic substances)
4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 7,500,000 shares of common stock, par value $0.0001 per share (“Stock”), of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to 1,125,000 additional shares of Stock (the “Optional Shares”) (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”). In the event that the Company has a single subsidiary or does not have any subsidiaries, then all references herein to “subsidiaries” of the Company shall be deemed to refer to such single subsidiary or to the Company, respectively, mutatis mutandis.
Kodiak Gas Services, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 31st, 2023 • Kodiak Gas Services, Inc. • Natural gas transmission
Kodiak Gas Services Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ⚫ ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ ⚫ ] additional shares (the “Optional Shares”) of common stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Atlas Energy Solutions Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • March 14th, 2023 • Atlas Energy Solutions Inc. • Mining & quarrying of nonmetallic minerals (no fuels)
Atlas Energy Solutions Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 18,000,000 shares of its Class A common stock, par value $0.01 per share, of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to 2,700,000 additional shares (the “Optional Shares”) of Class A common stock of the Company (the “Stock”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares.”
American Water Works Company, Inc.Underwriting Agreement • March 3rd, 2023 • American Water Works Company, Inc. • Water supply
Atlas Energy Solutions Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • February 24th, 2023 • Atlas Energy Solutions Inc. • Mining & quarrying of nonmetallic minerals (no fuels)
Atlas Energy Solutions Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares of its Class A common stock, par value $0.01 per share, of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Class A common stock of the Company (the “Stock”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares.”
Terreno Realty Corporation Common Stock Underwriting AgreementUnderwriting Agreement • February 13th, 2023 • Terreno Realty Corp • Real estate
Terreno Realty Corporation, a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC and KeyBanc Capital Markets Inc. are acting as representatives (together, the “Representatives” or “you”), an aggregate of 5,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 750,000 additional shares (the “Optional Shares”) of its common stock, par value $0.01 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
VOR BIOPHARMA INC. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • December 7th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances)
Corsair Gaming, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • November 18th, 2022 • Corsair Gaming, Inc. • Computer peripheral equipment, nec • New York
Corsair Gaming, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,545,455 shares of common stock (“Stock”) of the Company (the “Firm Shares”), and, at the election of the Underwriters, up to 681,818 additional shares of Stock (the “Optional Shares”), subject to the terms and conditions stated in this Agreement.
Taysha Gene Therapies, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 27th, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • New York
Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as the representative (the “Representative”), an aggregate of 14,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,100,000 additional shares (the “Optional Shares”) of common stock, par value $0.00001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Amylyx Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 4th, 2022 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Mobileye Global Inc. [●] shares of Class A Common Stock Underwriting AgreementUnderwriting Agreement • September 30th, 2022 • Mobileye Global Inc. • Services-prepackaged software • New York
Mobileye Global Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Class A common stock, par value $0.01 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Allakos Inc. 29,882,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • September 19th, 2022 • Allakos Inc. • Pharmaceutical preparations • New York
Allakos Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 29,882,000 shares (the “Shares”).
Karuna Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • August 11th, 2022 • Karuna Therapeutics, Inc. • Pharmaceutical preparations • New York
Karuna Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 3,488,373 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 523,255 additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
CinCor Pharma, Inc. Common Stock, $0.00001 Par Value Per Share Underwriting AgreementUnderwriting Agreement • August 8th, 2022 • CinCor Pharma, Inc. • Pharmaceutical preparations • New York
CinCor Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of [•] shares (the “Firm Shares”) of common stock, $0.00001 par value per share (“Stock”) of the Company (the Firm Shares and (ii) pre-funded warrants to purchase up to an aggregate of [•] shares of Stock (the “Pre-Funded Warrants”) at an exercise price of $[•] per share. In addition, the Company proposes, subject to the terms and conditions stated in this Agreement, to issue and sell to the Underwriters, at the election of the Underwriters, up to [•] additional shares of Stock (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively referred to as the “Shares.” The shares of Stock issuable upon exercise of the Pre-Funded Warrants are h
Arcutis Biotherapeutics, Inc. Common Stock, Par Value $0.0001 per Share Underwriting AgreementUnderwriting Agreement • August 5th, 2022 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • New York
Arcutis Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 7,500,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock,” and such shares the “Firm Shares”) and, at the election of the Underwriters, up to 1,125,000 additional shares (the “Optional Shares”) of Common Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Artiva Biotherapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 21st, 2022 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Common Stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Justworks, Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • January 4th, 2022 • Justworks, Inc. • Services-prepackaged software • New York
Justworks, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [l] shares and, at the election of the Underwriters, up to [l] additional shares of Class A Common Stock, par value $0.0005 per share (“Class A Common Stock”) of the Company. The aggregate of [l] shares of Class A Common Stock to be sold by the Company is herein called the “Firm Shares” and the aggregate of [l] additional shares of Class A Common Stock to be sold by the Company is herein called the “Optional Shares”. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
Amylyx Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 3rd, 2022 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Peloton Interactive, Inc. Class A Common Stock, Par Value $0.000025 per share Underwriting AgreementUnderwriting Agreement • November 18th, 2021 • Peloton Interactive, Inc. • Sporting & athletic goods, nec • New York
Peloton Interactive, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLCand J.P. Morgan Securities LLC are acting as representatives (the “Representatives”), an aggregate of 23,913,043 shares of Class A common stock, par value $0.000025 per share (“Class A Common Stock”) of the Company and, at the election of the several Underwriters, up to 3,260,869 additional shares of Class A Common Stock. The aggregate of 23,913,043 shares of Class A Common Stock to be sold by the Company is herein called the “Firm Shares” and the aggregate of up to 3,260,869 additional shares of Class A Common Stock to be sold by the Company at the election of the Underwriters is herein called the “Optional Shares”. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant t
Arrival 25,000,000 Ordinary Shares Underwriting AgreementUnderwriting Agreement • November 17th, 2021 • Arrival • Motor vehicles & passenger car bodies • New York
Arrival (formerly Arrival Group), a joint stock company (société anonyme) governed by the laws of the Grand Duchy of Luxembourg having its registered office at 1, rue Peternelchen L-2370 Howald, Grand Duchy of Luxembourg, registered with the Luxembourg register of commerce and companies (Registre de Commerce et des Sociétés de Luxembourg) under number B 248209 (the “Company”) proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 25,000,000 ordinary shares of the Company (each, an “Ordinary Share”) and, at the election of the
Terreno Realty Corporation Common Stock Underwriting AgreementUnderwriting Agreement • November 8th, 2021 • Terreno Realty Corp • Real estate • New York
Terreno Realty Corporation, a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC and KeyBanc Capital Markets Inc. are acting as representatives (together, the “Representatives” or “you”), an aggregate of 3,500,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 525,000 additional shares (the “Optional Shares”) of its common stock, par value $0.01 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Lulu’s Fashion Lounge Holdings, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • November 1st, 2021 • Lulu's Fashion Lounge Holdings, Inc. • Retail-catalog & mail-order houses • New York
Lulu’s Fashion Lounge Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of [•] shares of common stock, par value $0.001 per share (“Stock”) of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares of Stock. The aggregate of [•] shares of Stock to be sold by the Company is herein called the “Firm Shares” and the aggregate of up to [•] additional shares of Stock to be sold by the Company is herein called the “Optional Shares.” The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • October 26th, 2021 • 4D Molecular Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”). In the event that the Company has a single subsidiary or does not have any subsidiaries, then all references herein to “subsidiaries” of the Company shall be deemed to refer to such single subsidiary or to the Company, respectively, mutatis mutandis.
LianBio [•] American Depositary Shares Representing [•] Ordinary Shares, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • October 20th, 2021 • LianBio • Pharmaceutical preparations
LianBio, an exempted company organized under the Laws of the Cayman Islands (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] American Depositary Shares, each representing [•] ordinary share[s], par value $0.0001 per share (the “Ordinary Shares”), of the Company and, at the election of the Underwriters, up to [•] additional American Depositary Shares representing [•] Ordinary Shares. The aggregate of [•] American Depositary Shares representing [•] Ordinary Shares to be sold by the Company is herein called the “Firm ADSs”, and the aggregate of [•] American Depositary Shares representing [•] additional Ordinary Shares to be sold by the Company is called the “Optional ADSs”. The Firm ADSs and the Optional ADSs that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “ADSs”. The Ordinary S
